Odd Coupling: J&J, RallyBio Collaborate As Only Firms Focused On FNAIT

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

While not co-developing each other’s drugs, J&J and financially troubled RallyBio are working on complementary approaches to the rare disease fetal and neonatal alloimmune thrombocytopenia.

Fetal
RallyBio hopes its antibody can prevent the rare disease FNAIT • Source: Shutterstock

About two months after announcing that it was reducing its workforce by 45% and focusing on two core R&D programs, Rallybio Corp. has gotten support from pharma giant Johnson & Johnson for its efforts to develop a therapy to prevent a rare disease that can cause uncontrolled bleeding in fetuses and infants. J&J has nipocalimab in Phase III to treat the disorder – fetal and neonatal alloimmune thrombocytopenia (FNAIT) – so the companies decided to make their efforts complementary while stopping short of a co-development arrangement.

Key Takeaways

  • RallyBio and Johnson & Johnson are collaborating on disease awareness of rare disorder FNAIT, which can cause serious fetal bleeding and lead to death.

On 10 April, RallyBio announced a collaboration with J&J aimed at disease awareness about FNAIT, while also revealing that Johnson...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Rare Diseases

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Merck’s Winrevair Approved For PAH In Europe As Initial US Launch Progresses

 
• By Mandy Jackson

Merck & Co. won European Commission approval for Winrevair on top of other medicines for pulmonary arterial hypertension and expects an initial EU launch in Germany.

BioMarin Recruits Amgen R&D’s Friberg, Roche Dealmaker Sabry To Leadership Team

 
• By Mandy Jackson

The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.

Gene Therapy Patient Pipeline Builds, But Slowly, In Q2

 
• By Jessica Merrill

Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area. 

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains